Pulmonary hypertension in sarcoidosis: A review

Respirology

Volumn 16, Issue 1, 2011, Pages 69-77

  Corte, Tamera J ^a   Wells, Athol U ^a,b   Nicholson, Andrew G ^a,b   Hansell, David M ^a,b   Wort, Stephen J ^a,b  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Mortality; Pathophysiology; Pulmonary hypertension; Sarcoidosis; Treatment

Indexed keywords

BOSENTAN; CORTICOSTEROID; ENDOTHELIN 1; NATRIURETIC FACTOR; PROSTACYCLIN; SILDENAFIL;

CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; ELECTROCARDIOGRAM; EXERCISE TEST; HEART CATHETER; HUMAN; LUNG BLOOD VESSEL; LUNG FUNCTION; LUNG SARCOIDOSIS; LUNG TRANSPLANTATION; LUNG VASOCONSTRICTION; MYOCARDIAL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PORTOPULMONARY HYPERTENSION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY VENO-OCCLUSIVE DISEASE; REVIEW; RISK FACTOR;

CARDIOMYOPATHIES; ENDOTHELIN-1; HUMANS; HYPERTENSION, PULMONARY; LUNG; NATRIURETIC PEPTIDE, BRAIN; SARCOIDOSIS, PULMONARY; VASOCONSTRICTION;

EID: 79952275862     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2010.01872.x     Document Type: Review

References (61)

1. Shigemitsu H, Nagai S, Sharma OP. Pulmonary hypertension and granulomatous vasculitis in sarcoidosis. Curr. Opin. Pulm. Med. 2007; 13: 434-8. (Pubitemid 47472307)
2. Battesti JP, Georges R, Basset F et al. Chronic cor pulmonale in pulmonary sarcoidosis. Thorax 1978; 33: 76-84. (Pubitemid 8281616)
3. Rizzato G, Pezzano A, Sala G et al. Right heart impairment in sarcoidosis: haemodynamic and echocardiographic study. Eur. J. Respir. Dis. 1983; 64: 121-8. (Pubitemid 13181058)
4. Mayock RL, Bertrand P, Morrison CE et al. Manifestations of sarcoidosis. Analysis of 145 patients, with a review of nine series selected from the literature. Am. J. Med. 1963; 35: 67-89.
5. Shorr AF, Helman DL, Davies DB et al. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur. Respir. J. 2005; 25: 783-8. (Pubitemid 40667674)
6. Shorr AF, Davies DB, Nathan SD. Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest 2003; 124: 922-8. (Pubitemid 37123310)
7. Arcasoy SM, Christie JD, Pochettino A et al. Characteristics and outcomes of patients with sarcoidosis listed for lung transplantation. Chest 2001; 120: 873-80. (Pubitemid 32885463)
8. Shorr AF, Davies DB, Nathan SD. Outcomes for patients with sarcoidosis awaiting lung transplantation. Chest 2002; 122: 233-8. (Pubitemid 34754168)
9. Simonneau G, Robbins IM, Beghetti M et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 2009; 54: S43-54.
10. Baughman RP. Pulmonary hypertension associated with sarcoidosis. Arthritis Res. Ther. 2007; 9 (Suppl. 2): S8.
11. Handa T, Nagai S, Miki S et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest 2006; 129: 1246-52.
12. Gluskowski J, Hawrylkiewicz I, Zych D et al. Pulmonary haemodynamics at rest and during exercise in patients with sarcoidosis. Respiration 1984; 46: 26-32. (Pubitemid 14054225)
13. Gluskowski J, Hawrylkiewicz I, Zych D et al. Effects of corticosteroid treatment on pulmonary haemodynamics in patients with sarcoidosis. Eur. Respir. J. 1990; 3: 403-7. (Pubitemid 20163935)
14. Baughman RP, Engel PJ, Meyer CA et al. Pulmonary hypertension in sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. 2006; 23: 108-16. (Pubitemid 47471829)
15. Sulica R, Teirstein AS, Kakarla S et al. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest 2005; 128: 1483-9. (Pubitemid 41324436)
16. Nunes H, Humbert M, Capron F et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 2006; 61: 68-74. (Pubitemid 43106981)
17. Emirgil C, Sobol BJ, Herbert WH et al. The lesser circulation in pulmonary fibrosis secondary to sarcoidosis and its relationship to respiratory function. Chest 1971; 60: 371-8.
18. Baughman RP, Engel PJ, Taylor L et al. Survival in sarcoidosis associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest 2010. DOI: 10.1378/09-2002.
19. Orens JB, Estenne M, Arcasoy S et al. International guidelines for the selection of lung transplant candidates: 2006 update - a consensus report fromthe Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J. Heart Lung Transplant. 2006; 25: 745-55.
20. Mitchell DN, Scadding JG. Sarcoidosis. Am. Rev. Respir. Dis. 1974; 110: 774-802.
21. Smith LJ, Lawrence JB, Katzenstein AA. Vascular sarcoidosis: a rare cause of pulmonary hypertension. Am. J. Med. Sci. 1983; 285: 38-44. (Pubitemid 13188569)
22. Damuth TE, Bower JS, Cho K et al. Major pulmonary artery stenosis causing pulmonary hypertension in sarcoidosis. Chest 1980; 78: 888-91. (Pubitemid 11209641)
23. Morawiec E, Hachulla-Lemaire AL, Chabrol J et al. Venoatrial compression by lymphadenopathy in sarcoidosis. Eur. Respir. J. 2010; 35: 1188-91.
24. Hamilton-Craig CR, Slaughter R, McNeil K et al. Improvement after angioplasty and stenting of pulmonary arteries due to sarcoid mediastinal fibrosis. Heart Lung Circ. 2009; 18: 222-5.
25. Toonkel RL, Borczuk AC, Pearson GD et al. Sarcoidosis-associated fibrosing mediastinitis with resultant pulmonary hypertension: a case report and review of the literature. Respiration 2009; 79: 341-5.
26. Fisher KA, Serlin DM, Wilson KC et al. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest 2006; 130: 1481-8. (Pubitemid 44786743)
27. Preston IR, Klinger JR, Landzberg MJ et al. Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. Chest 2001; 120: 866-72. (Pubitemid 32885462)
28. Barst RJ, Ratner SJ. Sarcoidosis and reactive pulmonary hypertension. Arch. Intern. Med. 1985; 145: 2112-14. (Pubitemid 16198417)
29. Jones K, Higenbottam T, Wallwork J. Pulmonary vasodilation with prostacyclin in primary and secondary pulmonary hypertension. Chest 1989; 96: 784-9. (Pubitemid 19256178)
30. Milman N, Svendsen CB, Iversen M et al. Sarcoidosis-associated pulmonary hypertension: acute vasoresponsiveness to inhaled nitric oxide and the relation to long-termeffect of sildenafil. Clin. Respir. J. 2009; 3: 207-13.
31. Hoffstein V, Ranganathan N, Mullen JB. Sarcoidosis simulating pulmonary veno-occlusive disease. Am. Rev. Respir. Dis. 1986; 134: 809-11. (Pubitemid 16008649)
32. Jones RM, Dawson A, Jenkins GH et al. Sarcoidosis-related pulmonary veno-occlusive disease presenting with recurrent haemoptysis. Eur. Respir. J. 2009; 34: 517-20.
33. Salazar A, Mana J, Sala J et al. Combined portal and pulmonary hypertension in sarcoidosis. Respiration 1994; 61: 117-19. (Pubitemid 24125937)
34. Rosen Y, Moon S, Huang CT et al. Granulomatous pulmonary angiitis in sarcoidosis. Arch. Pathol. Lab. Med. 1977; 101: 170-4. (Pubitemid 8187786)
35. Takemura T, Matsui Y, Saiki S et al. Pulmonary vascular involvement in sarcoidosis: a report of 40 autopsy cases. Hum. Pathol. 1992; 23: 1216-23.
36. Luscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000; 102: 2434-40.
37. Galie N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc. Res. 2004; 61: 227-37. (Pubitemid 38091763)
38. Pollock DM, Keith TL, Highsmith RF. Endothelin receptors and calcium signaling. FASEB J. 1995; 9: 1196-204.
39. Jozsef L, Khreiss T, Fournier A et al. Extracellular signal-regulated kinase plays an essential role in endothelin-1-induced homotypic adhesion of human neutrophil granulocytes. Br. J. Pharmacol. 2002; 135: 1167-74. (Pubitemid 34259117)
40. Eddahibi S, Springall D, Mannan M et al. Dilator effect of endothelins in pulmonary circulation: changes associated with chronic hypoxia. Am. J. Physiol. 1993; 265: L571-80.
41. Reichenberger F, Schauer J, Kellner K et al. Different expression of endothelin in the bronchoalveolar lavage in patients with pulmonary diseases. Lung 2001; 179: 163-74. (Pubitemid 34033112)
42. Terashita K, Kato S, Sata M et al. Increased endothelin-1 levels of BAL fluid in patients with pulmonary sarcoidosis. Respirology 2006; 11: 145-51. (Pubitemid 43356893)
43. Letizia C, Danese A, Reale MG et al. Plasma levels of endothelin-1 increase in patients with sarcoidosis and fall after disease remission. Panminerva Med. 2001; 43: 257-61. (Pubitemid 33633314)
44. Diaz-Guzman E, Farver C, Parambil J et al. Pulmonary hypertension caused by sarcoidosis. Clin. Chest Med. 2008; 29: 549-63, x.
45. Baughman RP, Sparkman BK, Lower EE. Six-minute walk test and health status assessment in sarcoidosis. Chest 2007; 132: 207-13. (Pubitemid 47068223)
46. Arcasoy SM, Christie JD, Ferrari VA et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am. J. Respir. Crit. Care Med. 2003; 167: 735-40. (Pubitemid 36801751)
47. Leuchte HH, Baumgartner RA, Nounou ME et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am. J. Respir. Crit. Care Med. 2006; 173: 744-50.
48. Corte TJ, Wort SJ, Gatzoulis MA et al. Elevated Brain natriuretic peptide predicts mortality in interstitial lung disease. Eur. Respir. J. 2010; 36: 819-25. DOI: 10.1183/09031936.00173509.
49. Handa T, Nagai S, Shigematsu M et al. Patient characteristics and clinical features of Japanese sarcoidosis patients with low bronchoalveolar lavage CD4/CD8 ratios. Sarcoidosis Vasc. Diffuse Lung Dis. 2005; 22: 154-60. (Pubitemid 41020023)
50. Bourbonnais JM, Samavati L. Clinical predictors of pulmonary hypertension in sarcoidosis. Eur. Respir. J. 2008; 32: 296-302.
51. Zisman DA, Karlamangla AS, Ross DJ et al. High-resolution chest CT findings do not predict the presence of pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Chest 2007; 132: 773-9.
52. Devaraj A, Wells AU, Meister MG et al. The effect of diffuse pulmonary fibrosis on the reliability of CT signs of pulmonary hypertension. Radiology 2008; 249: 1042-9.
53. Rodman DM, Lindenfeld J. Successful treatment of sarcoidosis-associated pulmonary hypertension with corticosteroids. Chest 1990; 97: 500-2. (Pubitemid 20050708)
54. Mangla A, Fisher J, Libby DM et al. Sarcoidosis, pulmonary hypertension, and acquired peripheral pulmonary artery stenosis. Cathet. Cardiovasc. Diagn. 1985; 11: 69-74. (Pubitemid 15149304)
55. Davies J, Nellen M, Goodwin JF. Reversible pulmonary hypertension in sarcoidosis. Postgrad. Med. J. 1982; 58: 282-5. (Pubitemid 12124776)
56. Foley RJ, Metersky ML. Successful treatment of sarcoidosis-associated pulmonary hypertension with bosentan. Respiration 2008; 75: 211-14. (Pubitemid 351363878)
57. Sharma S, Kashour T, Philipp R. Secondary pulmonary arterial hypertension: treated with endothelin receptor blockade. Tex. Heart Inst. J. 2005; 32: 405-10. (Pubitemid 41306807)
58. Pitsiou GG, Spyratos D, Kioumis I et al. Sarcoidosis-associated pulmonary hypertension: a role for endothelin receptor antagonists? Ther. Adv. Respir. Dis. 2009; 3: 99-101.
59. Milman N, Burton CM, Iversen M et al. Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil? J. Heart Lung Transplant. 2008; 27: 329-34. (Pubitemid 351375107)
60. Barnett CF, Bonura EJ, Nathan SD et al. Treatment of sarcoidosis- associated pulmonary hypertension. A two-center experience. Chest 2009; 135: 1455-61.
61. Heresi GA, Dweik RA. Sarcoidosis-associated pulmonary hypertension. One size does not fit all. Chest 2009; 135: 1410-12.